GALT
GALT clinical trials: GALECTIN THERAPEUTICS INC
Every trial on ClinicalTrials.gov where GALECTIN THERAPEUTICS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 10
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
GALT on the catalyst calendar · GALT registry changes
- Primary completion Mar 9, 2022ActualPhase 1NCT04332432GT-032 Belapectin Hepatic ImpairmentGalectin Therapeutics Inc. · Hepatic ImpairmentCompletedGALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 11, 2025ActualPhase 2/Phase 3NCT04365868Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH CirrhosisGalectin Therapeutics Inc. · Prevention of Esophageal VaricesTerminatedGALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2017ActualPhase 2NCT02462967Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension...Galectin Therapeutics Inc. · Hypertension, PortalCompletedGALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 27, 2016ActualPhase 2NCT02421094Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced FibrosisGalectin Therapeutics Inc. · Nonalcoholic SteatohepatitisCompletedGALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2018ActualPhase 2NCT02407041An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of PsoriasisGalectin Therapeutics Inc. · PsoriasisCompletedGALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2009ActualPhase 2NCT00388700A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal CancerGalectin Therapeutics Inc. · Colorectal CancerWithdrawnGALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2009ActualPhase 2NCT00386516Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder CancerGalectin Therapeutics Inc. · Cancer of the Bile DuctWithdrawnGALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2015ActualPhase 1NCT01899859Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced FibrosisGalectin Therapeutics Inc. · Non-Alcoholic Steatohepatitis (NASH)CompletedGALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2005ActualPhase 1NCT00054977Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid TumorsGalectin Therapeutics Inc. · Colorectal CancerCompletedGALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2007ActualPhase 2NCT00110721GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal CancerGalectin Therapeutics Inc. · Colorectal CancerTerminatedGALTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2021ActualPhase 1NCT02575404GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer PatientsProvidence Health & Services · MelanomaCompletedGALTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 28, 2018ActualPhase 1NCT02117362Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic MelanomaProvidence Health & Services · Metastatic MelanomaCompletedGALTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner